08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Cipher, Galephar Pharmaceutical Research Inc., Kowa deal

Cipher received a $1 million milestone from Kowa after the pharma achieved a cumulative sales milestone for Lipofen ( CIP-fenofibrate ). Manufacturing partner Galephar is eligible for 50% of milestone and royalties payments on the...
07:00 , May 9, 2011 |  BC Week In Review  |  Clinical News

Antara fenofibrate regulatory update

FDA issued a new quarterly report on safety information emerging from its Adverse Events Reporting System (AERS) during 4Q10 in which the agency identified a "paradoxical" reduction in HDL cholesterol in patients receiving fenofibrate products....
07:00 , Jul 12, 2010 |  BC Week In Review  |  Company News

Cipher, Kowa sales and marketing update

Cipher received a $1 million milestone from Kowa after the pharma achieved a cumulative sales milestone for Lipofen ( CIP-fenofibrate ). Kowa has rights to market the gelatin capsule containing fenofibrate through its 2008 acquisition...
07:00 , Aug 11, 2008 |  BC Week In Review  |  Company News

ProEthic, Kowa deal

Japanese conglomerate Kowa acquired ProEthic for an undisclosed sum as an entry into the U.S. pharmaceutical market. The first new product to be launched by the acquired company, which will be renamed Kowa Pharmaceuticals America,...
08:00 , Feb 7, 2008 |  BC Innovations  |  Targets & Mechanisms

PPAR-alpha's in cancer

In a paper published in the Proceedings of the National Academy of Sciences , Harvard University researchers demonstrated an anticancer effect in mice taking oral doses of the generic dyslipidemia drug fenofibrate. 1 The good...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

ProEthic sales and marketing update

ProEthic launched Lipofen ( CIP-fenofibrate ) in the U.S. to treat hyperlipidemia. ProEthic has exclusive rights to market the gelatin capsule containing fenofibrate in the U.S. from Cipher Pharmaceuticals Inc. (TSX:DND, Mississauga, Ontario). The wholesale...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Company News

Cipher, ProEthic sales and marketing update

ProEthic received exclusive rights to market DND's Lipofen ( CIP-fenofibrate ) in the U.S. to treat hyperlipidemia. DND will receive $2 million up front and is eligible for up to $20 million in milestones, plus...
08:00 , Feb 27, 2006 |  BC Week In Review  |  Clinical News

CIP-Fenofibrate regulatory update

DND received marketing approval in Canada for CIP-Fenofibrate to treat hyperlipidemia. The gelatine capsule containing fenofibrate was approved in the U.S. last month (see BioCentury, Jan. 16). Cipher Pharmaceuticals Inc. (TSX:DND), Mississauga, Ontario   Product:...
08:00 , Jan 16, 2006 |  BC Week In Review  |  Clinical News

Lipofen fenofibrate capsules regulatory update

FDA approved an NDA for 50, 100 and 150 mg Lipofen gelatine capsules containing fenofibrate as an adjunctive therapy to diet to reduce elevated LDL-C, total cholesterol, triglycerides, apolipoprotein B (Apo B), to increase HDL-C...